I Hate Dialysis Message Board
Welcome, Guest. Please login or register.
June 17, 2024, 06:29:15 PM

Login with username, password and session length
Search:     Advanced search
532606 Posts in 33561 Topics by 12678 Members
Latest Member: astrobridge
* Home Help Search Login Register
+  I Hate Dialysis Message Board
|-+  Dialysis Discussion
| |-+  Dialysis: News Articles
| | |-+  *** Denver-based DaVita settles case on overuse of EPO ***
0 Members and 1 Guest are viewing this topic. « previous next »
Pages: [1] Go Down Print
Author Topic: *** Denver-based DaVita settles case on overuse of EPO ***  (Read 4385 times)
Elite Member
Offline Offline

Gender: Male
Posts: 4820

"Still crazy after all these years."

« on: July 08, 2012, 10:31:09 AM »

Denver-based DaVita settles case on overuse of kidney care drug

POSTED:   07/04/2012 01:00:00 AM MDT
By Michael Booth and Christopher N. Osher
The Denver Post


Kidney dialysis giant DaVita Inc. has settled a whistleblower lawsuit for the first time, agreeing to pay $55 million over allegations of drug overuse while denying any wrongdoing.

Denver-based DaVita settled fraud claims in a Texas lawsuit challenging the dialysis chain's past use of Epogen, an anemia drug whose high cost and dangers helped change how the government pays for kidney care.

DaVita said the $55 million settlement with Ivey Woodard, a former employee of Epogen-maker Amgen, would impact its second-quarter earnings. Attorneys fees will add to the total.

The federal government, which pays for most dialysis through Medicare, will get more than 70 percent of the settlement, the whistleblower's attorney said.

Wall Street shrugged off the news, with company stock rising nine cents Tuesday to $97.71, up more than $28 since the beginning of 2011. The company has predicted a rise in operating income up to $1.3 billion this year.

DaVita still faces ongoing legal action over its drug use in other states, as well as a federal grand jury investigation in Denver over its financial arrangements with kidney doctors.

DaVita said it was the first time it was settling a claim over federal anti-fraud laws, but noted the government had declined to join the whistleblower' s lawsuit.

"DaVita and its affiliated physicians did nothing wrong and stand by their anemia management practices, which were always consistent with their mission of providing the best possible care for each patient," a company statement said. The suit was first filed in 2002.

Most kidney dialysis patients are anemic. Epogen, made by Amgen, is commonly used in dialysis clinics to boost patients' red blood cell counts back to healthy levels. Medicare pays the bills of long-term dialysis patients.

The Texas whistleblower lawsuit accused DaVita of using more Epogen than was medically necessary, and for double-billing the government for Epogen left over in vials and reused. For the period covered by the lawsuit, the payment system rewarded dialysis companies by reimbursing for the amount of drugs used, critics have said.

Woodard and attorneys thought they could prove "DaVita was pushing the envelope and pushing the boundary of what would be good medical practice" by using more Epogen than patients needed in order to boost profits, Caddell said last year in commenting on the suit.

Whistleblowers can win percentages of judgments if courts agree health care companies defrauded the government. Government investigators can formally join the lawsuits to recover Medicare and Medicaid money, and judgments may reach into the hundreds of millions of dollars. In the Woodard case, the government had not joined the action.

In responding in the past to questions about lawsuits and other challenges, DaVita had said that physicians are the ones who make Epogen decisions and prescribe treatment. DaVita has also said in court responses that the government was aware of how dialysis companies used "overfill" in Epogen vials.

Since the years when doctors and other critics raised questions about overuse of Epogen, Medicare has reversed the way it pays dialysis companies. It now bundles dialysis-related services and drugs into one set payment, with targets for red blood cell counts and other measures. The incentive is now to use less of the drugs, analysts have said.

Patient advocates are still mistrustful of how the large dialysis chains make a profit.

"We should worry now about under use" of drugs "because the incentives have flipped 180 degrees," said Bill Peckham, a dialysis patient who runs an advocacy newsletter from Washington state.

In November, Kent Thiry, the chief executive of DaVita, said a federal grand jury in Denver was looking into partnerships between DaVita and a group of kidney doctors. At that time, he was responding to questions from stock analysts about an article in The Denver Post about the kidney dialysis firm's relationship with Denver Nephrology Inc.

Jeff Dorschner, a spokesman for the U.S. Attorney's Office in Colorado, declined comment Tuesday when asked about the status of that grand jury investigation. DaVita said it was ongoing.

In 2008, DaVita sold 49 percent ownership in seven dialysis clinics to Denver Nephrology for $1.89 million. Those clinics generated estimated annual revenues of more than $28 million.

That sale took place 17 months after DaVita offered the 40 percent ownership in the clinics to another group of Denver doctors for eight times the eventual purchase price. DaVita has said the value of the clinics plunged because a major dialysis competitor was coming to Denver.

Federal law says dialysis companies must sell part-ownership of clinics at market value.

Michael Booth: 303-954-1686 or mbooth@denverpost.com; Twitter: @MBoothdp

Uninterrupted in-center (self-care) hemodialysis since 1982 -- 34 YEARS on March 3, 2016 !!
No transplant.  Not yet, anyway.  Only decided to be listed on 11/9/06. Inactive at the moment.  ;)
I make films.

Just the facts: 70.0 kgs. (about 154 lbs.)
Treatment: Tue-Thur-Sat   5.5 hours, 2x/wk, 6 hours, 1x/wk
Dialysate flow (Qd)=600;  Blood pump speed(Qb)=315
Fresenius Optiflux-180 filter--without reuse
Fresenius 2008T dialysis machine
My KDOQI Nutrition (+/ -):  2,450 Calories, 84 grams Protein/day.

"Living a life, not an apology."
Full Member
Offline Offline

Gender: Male
Posts: 445

« Reply #1 on: July 08, 2012, 10:38:06 AM »

"We should worry now about under use" of drugs "because the incentives have flipped 180 degrees," said Bill Peckham, a dialysis patient who runs an advocacy newsletter from Washington state.
That's for sure! Way to go Bill.  :clap;

Bill Peckham
Elite Member
Offline Offline

Gender: Male
Posts: 3057

« Reply #2 on: July 08, 2012, 11:17:24 AM »

Thanks Zach I hadn't seen this, you'd think they'd tell me these things.

Thanks Willis.

http://www.billpeckham.com  "Dialysis from the sharp end of the needle" tracking  industry news and trends - in advocacy, reimbursement, politics and the provision of dialysis
Incenter Hemodialysis: 1990 - 2001
Home Hemodialysis: 2001 - Present
NxStage System One Cycler 2007 - Present
        * 4 to 6 days a week 30 Liters (using PureFlow) @ ~250 Qb ~ 8 hour per treatment FF~28
Member for Life
Offline Offline

Gender: Female
Posts: 7536


« Reply #3 on: July 08, 2012, 01:00:04 PM »

They only quoted you - why on earth would they have gone to all the effort to let you know or ask permission!   :sarcasm;

After all, you've only got a website - there's no quick and convenient way to contact you.   ;D


"Asbestos Gelos"  (As-bes-tos yay-lohs) Greek. Literally, "fireproof laughter".  A term used by Homer for invincible laughter in the face of death and mortality.

Sr. Member
Offline Offline

Gender: Male
Posts: 654

I only look like a sheep - but I ain't

« Reply #4 on: July 08, 2012, 06:14:54 PM »

And to go down memory lane, here is an article from 2008:

"Unlike not-for-profit dialysis centers, which reduced doses of the anemia drug Epogen after they reached recommended hematocrit levels, for-profit centers continued to increase doses, sometimes to three times that of non-profit centers."


Sorry, been kind of cranky ever since davita moved into the neighborhood.

And of course, way to keep them on their toes Bill!!

Proud member of DialysisEthics since 2000

DE responsible for:

*2000 US Senate hearings

*Verified statistics on "Dialysis Facility Compare"

*Doctors have to review charts before they can be reimbursed

*2000 and 2003 Office of Inspector General (OIG) reports on the conditions in dialysis

*2007 - Members of DialysisEthics worked for certification of hemodialysis
technicians in Colorado - bill passed, renewed in 2012 and 2019

*1999 to present - nonviolent dismissed patients returned to their
clinics or placed in other clinics or hospitals over the years

On my tombstone: He was a good kind of crazy

« Reply #5 on: August 07, 2012, 01:36:08 AM »

« Last Edit: September 18, 2015, 05:03:49 PM by noahvale » Logged
Member for Life
Offline Offline

Gender: Female
Posts: 12242

Going through life tied to a chair!

« Reply #6 on: August 07, 2012, 03:07:36 AM »

I wonder what their hidden agenda is for sellling 40 percent of those 7 clinics for such a low price?

I still think that making such HUGE amounts of money off sick people and Medicare is wrong.

Pages: [1] Go Up Print 
« previous next »

Powered by MySQL Powered by PHP SMF 2.0.17 | SMF © 2019, Simple Machines | Terms and Policies Valid XHTML 1.0! Valid CSS!